Th1 cytokine-secreting recombinant Mycobacterium bovis bacillus Calmette-Guérin and prospective use in immunotherapy of bladder cancer

Clinical and Developmental Immunology

Volumn 2011, Issue , 2011, Pages

  Luo, Yi ^a   Henning, Jonathan ^a   O'Donnell, Michael A ^a  

^a UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BCG VACCINE; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HEAT SHOCK PROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 15; INTERLEUKIN 18; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; MITOMYCIN C; MONOCYTE CHEMOTACTIC PROTEIN 3; MUCIN 1; PROSTATE SPECIFIC MEMBRANE ANTIGEN; PROTEIN P21; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON; RECOMBINANT CYTOKINE; RECOMBINANT GAMMA INTERFERON; RECOMBINANT GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; RECOMBINANT INTERLEUKIN 12; RECOMBINANT INTERLEUKIN 2; TRANSCRIPTION FACTOR AP 1; TUMOR NECROSIS FACTOR ALPHA; UNINDEXED DRUG; VERY LATE ACTIVATION ANTIGEN 5; CANCER VACCINE; CYTOKINE; RECOMBINANT VACCINE;

APOPTOSIS; BACTERIAL STRAIN; BLADDER CANCER; BLADDER SPASM; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CARCINOMA IN SITU; CD4+ T LYMPHOCYTE; CELL CYCLE ARREST; CYTOLOGY; CYTOTOXICITY; DENDRITIC CELL; DRUG EFFICACY; DRUG SAFETY; DYSURIA; FLU LIKE SYNDROME; GENE EXPRESSION; GENE TARGETING; GENETIC ENGINEERING; HEMATURIA; HUMAN; IMMUNE RESPONSE; LOWER URINARY TRACT SYMPTOM; META ANALYSIS (TOPIC); MYALGIA; MYCOBACTERIUM BOVIS; MYCOBACTERIUM SMEGMATIS; NATURAL KILLER CELL; NONHUMAN; NONMUSCLE INVASIVE BLADDER CANCER; PHASE 3 CLINICAL TRIAL (TOPIC); POLYURIA; PRIORITY JOURNAL; PROMOTER REGION; PROPHYLAXIS; PYELOGRAPHY; REVIEW; SEPSIS; TH1 CELL; TRANSITIONAL CELL CARCINOMA; TRANSURETHRAL RESECTION; TREATMENT FAILURE; URINARY URGENCY; URINE LEVEL; UROTHELIUM; BIOSYNTHESIS; BLADDER TUMOR; GENE TRANSFER; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY;

BCG VACCINE; CANCER VACCINES; CYTOKINES; GENE TRANSFER TECHNIQUES; HUMANS; IMMUNOTHERAPY; TH1 CELLS; URINARY BLADDER NEOPLASMS; VACCINES, SYNTHETIC;

EID: 81555227857     PISSN: 17402522     EISSN: 17402530     Source Type: Journal    
DOI: 10.1155/2011/728930     Document Type: Review

References (129)

1. Jemal A., Siegel R., Xu J., Ward E., Cancer statistics CA Cancer Journal for Clinicians 2010 60 5 277 300
2. Williams S. K., Hoenig D. M., Ghavamian R., Soloway M., Intravesical therapy for bladder cancer Expert Opinion on Pharmacotherapy 2010 11 6 947 958
3. Morales A., Eidinger D., Bruce A. W., Intracavitary Bacillus Calmette-Guérin in the treatment of superficial bladder tumors Journal of Urology 1976 116 2 180 183
4. Hall M. C., Chang S. S., Dalbagni G., Pruthi R. S., Seigne J. D., Skinner E. C., Wolf J. S., Schellhammer P. F., Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update Journal of Urology 2007 178 6 2314 2330 (Pubitemid 350080987)
5. Babjuk M., Oosterlinck W., Sylvester R., Kaasinen E., Bhle A., Palou-Redorta J., European Association of Urology (EAU), EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder The European Urology 2008 54 2 303 314
6. Lamm D. L., Blumenstein B. A., Crissman J. D., Montie J. E., Gottesman J. E., Lowe B. A., Sarosdy M. F., Bohl R. D., Grossman H. B., Beck T. M., Leimert J. T., Crawford E. D., Maintenance bacillus Calmette-Guérin immunotherapy for recurrent Ta, T1 and carcinoma in situ transitional cell carcinoma of the bladder: a randomized Southwest Oncology Group Study Journal of Urology 2000 163 4 1124 1129 (Pubitemid 30169376)
7. Brandau S., Suttmann H., Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement Biomedicine and Pharmacotherapy 2007 61 6 299 305 (Pubitemid 47189735)
8. Alexandroff A. B., Nicholson S., Patel P. M., Jackson A. M., Recent advances in bacillus Calmette-Guérin immunotherapy in bladder cancer Immunotherapy 2010 2 4 551 560
9. Kavoussi L. R., Brown E. J., Ritchey J. K., Ratliff T. L., Fibronectin-mediated Calmette-Guérin bacillus attachment to murine bladder mucosa. Requirement for the expression of an antitumor response Journal of Clinical Investigation 1990 85 1 62 67 (Pubitemid 20030291)
10. Becich M. J., Carroll S., Ratliff T. L., Internalization of bacille Calmette-Guérin by bladder tumor cells Journal of Urology 1991 145 6 1316 1324
11. Bevers R. F. M., Kurth K. H., Schamhart D. H. J., Role of urothelial cells in BCG immunotherapy for superficial bladder cancer The British Journal of Cancer 2004 91 4 607 612 (Pubitemid 39141611)
12. Bhle A., Gerdes J., Ulmer A. J., Hofstetter A. G., Flad H. D., Effects of local bacillus Calmette-Guérin therapy in patients with bladder carcinoma on immunocompetent cells of the bladder wall Journal of Urology 1990 144 1 53 58 (Pubitemid 20221267)
13. Prescott S., James K., Hargreave T. B., Chisholm G. D., Smyth J. F., Intravesical Evans strain BCG therapy: quantitative immunohistochemical analysis of the immune response within the bladder wall Journal of Urology 1992 147 6 1636 1642
14. Saban M. R., Simpson C., Davis C., Wallis G., Knowlton N., Frank M. B., Centola M., Gallucci R. M., Saban R., Discriminators of mouse bladder response to intravesical Bacillus Calmette-Guérin (BCG) BMC Immunology 2007 8, article 6
15. De Boer E. C., de Jong W. H., van der Meijden A. P., Steerenberg P. A., Witjes F., Vegt P. D. J., Debruyne F. M. J., Ruitenberg E. J., Leukocytes in the urine after intravesical BCG treatment for superficial bladder cancer. A flow cytofluorometric analysis Urological Research 1991 19 1 45 50
16. De Boer E. C., de Jong W. H., van der Meijden A. P., Steerenberg P. A., Witjes J. A., Vegt P. D. J., Debruyne F. M. J., Ruitenberg E. J., Presence of activated lymphocytes in the urine of patients with superficial bladder cancer after intravesical immunotherapy with bacillus Calmette-Guérin Cancer Immunology and Immunotherapy 1991 33 6 411 416
17. De Boer E. C., De Jong W. H., Steerenberg P. A., Van der Meijden A. P. M., Aarden L. A., Debruyne F. M. J., Ruitenberg E. J., Leukocytes and cytokines in the urine of superficial bladder cancer patients after intravesical immunotherapy with Bacillus Calmette-Guérine In Vivo 1991 5 6 671 677
18. Simons M. P., O'Donnell M. A., Griffith T. S., Role of neutrophils in BCG immunotherapy for bladder cancer Urologic Oncology 2008 26 4 341 345 (Pubitemid 351885380)
19. Bhle A., Nowc C., Ulmer A. J., Musehold J., Gerdes J., Hofstetter A. G., Flad H. D., Elevations of cytokines interleukin-1, interleukin-2 and tumor necrosis factor in the urine of patients after intravesical bacillus Calmette-Guérin immunotherapy Journal of Urology 1990 144 1 59 64 (Pubitemid 20221268)
20. De Reijke T. M., De Boer E. C., Kurth K. H., Schamhart D. H. J., Urinary cytokines during intravesical bacillus Calmette-Guérin therapy for superficial bladder cancer: processing, stability and prognostic value Journal of Urology 1996 155 2 477 482 (Pubitemid 26023528)
21. Taniguchi K., Koga S., Nishikido M., Yamashita S., Sakuragi T., Kanetake H., Saito Y., Systemic immune response after intravesical instillation of bacille Calmette-Guérin (BCG) for superficial bladder cancer Clinical and Experimental Immunology 1999 115 1 131 135 (Pubitemid 29030375)
22. Saint F., Patard J. J., Maille P., Soyeux P., Hoznek A., Salomon L., Abbou C. C., Chopin D. K., Prognostic value of a T helper 1 urinary cytokine response after intravesical bacillus Calmette-Guérin treatment for superficial bladder cancer Journal of Urology 2002 167 1 364 367 (Pubitemid 34024586)
23. Nadler R., Luo Y., Zhao W., Ritchey J. K., Austin J. C., Cohen M. B., O'Donnell M. A., Ratliff T. L., Interleukin 10 induced augmentation of delayed-type hypersensitivity (DTH) enhances Mycobacterium bovis bacillus Calmette-Guérin (BCG) mediated antitumour activity Clinical and Experimental Immunology 2003 131 2 206 216 (Pubitemid 36205130)
24. Luo Y., Chen X., O'Donnell M. A., Mycobacterium bovis bacillus Calmette-Guérin (BCG) induces human CC- and CXC-chemokines in vitro and in vivo Clinical and Experimental Immunology 2007 147 2 370 378 (Pubitemid 46096016)
25. Riemensberger J., Bhle A., Brandau S., IFN-gamma and IL-12 but not IL-10 are required for local tumour surveillance in a syngeneic model of orthotopic bladder cancer Clinical and Experimental Immunology 2002 127 1 20 26 (Pubitemid 34155453)
26. Heldwein K. A., Liang M. D., Andresen T. K., Thomas K. E., Marty A. M., Cuesta N., Vogel S. N., Fenton M. J., TLR2 and TLR4 serve distinct roles in the host immune response against Mycobacterium bovis BCG Journal of Leukocyte Biology 2003 74 2 277 286 (Pubitemid 38040425)
27. Pryor K., Goddard J., Goldstein D., Stricker P., Russell P., Golovsky D., Penny R., Bacillus Calmette-Guérin (BCG) enhances monocyte- and lymphocyte-mediated bladder tumour cell killing The British Journal of Cancer 1995 71 4 801 807
28. Yamada H., Matsumoto S., Matsumoto T., Yamada T., Yamashita U., Murine IL-2 secreting recombinant Bacillus Calmette-Guérin augments macrophage-mediated cytotoxicity against murine bladder cancer MBT-2 Journal of Urology 2000 164 2 526 531 (Pubitemid 30481978)
29. Luo Y., Yamada H., Chen X., Ryan A. A., Evanoff D. P., Triccas J. A., O'Donnell M. A., Recombinant Mycobacterium bovis bacillus Calmette-Guérin (BCG) expressing mouse IL-18 augmente Th1 immunity and macrophage cytotoxicity Clinical and Experimental Immunology 2004 137 1 24 34 (Pubitemid 38869774)
30. Luo Y., Yamada H., Evanoff D. P., Chen X., Role of Th1-stimulating cytokines in bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against mouse bladder cancer MBT-2 cells Clinical and Experimental Immunology 2006 146 1 181 188 (Pubitemid 44393852)
31. Luo Y., Han R., Evanoff D. P., Chen X., Interleukin-10 inhibits Mycobacterium bovis bacillus Calmette-Guérin (BCG)-induced macrophage cytotoxicity against bladder cancer cells Clinical and Experimental Immunology 2010 160 3 359 368
32. Jansson O. T., Morcos E., Brundin L., Lundberg J. O. N., Adolfsson J., Sderhll M., Wiklund N. P., The role of nitric oxide in bacillus Calmette-Guérin mediated anti-tumour effects in human bladder cancer The British Journal of Cancer 1998 78 5 588 592
33. Godaly G., Young D. B., Mycobacterium bovis bacille Calmette Guerin infection of human neutrophils induces CXCL8 secretion by MyD88-dependent TLR2 and TLR4 activation Cellular Microbiology 2005 7 4 591 601 (Pubitemid 40439457)
34. Suttmann H., Riemensberger J., Bentien G., Schmaltz D., Stckle M., Jocham D., Bhle A., Brandau S., Neutrophil granulocytes are required for effective Bacillus Calmette-Guérin immunotherapy of bladder cancer and orchestrate local immune responses Cancer Research 2006 66 16 8250 8257 (Pubitemid 44299194)
35. Ludwig A. T., Moore J. M., Luo Y., Chen X., Saltsgaver N. A., O'Donnell M. A., Griffith T. S., Tumor necrosis factor-related apoptosis-inducing ligand: a novel mechanism for Bacillus Calmette-Guérin-induced antitumor activity Cancer Research 2004 64 10 3386 3390 (Pubitemid 38657909)
36. Kemp T. J., Ludwig A. T., Earel J. K., Moore J. M., VanOosten R. L., Moses B., Leidal K., Nauseef W. M., Griffith T. S., Neutrophil stimulation with Mycobacterium bovis bacillus Calmette-Guérin (BCG) results in the release of functional soluble TRAIL/Apo-2L Blood 2005 106 10 3474 3482 (Pubitemid 41609183)
37. Suttmann H., Jacobsen M., Reiss K., Jocham D., Bhle A., Brandau S., Mechanisms of bacillus Calmette-Guérin mediated natural killer cell activation Journal of Urology 2004 172 4, part 1 1490 1495 (Pubitemid 39249755)
38. Liu W., O'Donnell M. A., Chen X., Han R., Luo Y., Recombinant bacillus Calmette-Guérin (BCG) expressing interferon-alpha 2B enhances human mononuclear cell cytotoxicity against bladder cancer cell lines in vitro Cancer Immunology and Immunotherapy 2009 58 10 1647 1655
39. Ratliff T. L., Ritchey J. K., Yuan J. J., Andriole G. L., Catalona W. J., T-cell subsets required for intravesical BCG immunotherapy for bladder cancer Journal of Urology 1993 150 3 1018 1023 (Pubitemid 23241327)
40. Brandau S., Riemensberger J., Jacobsen M., Kemp D., Zhao W., Zhao X., Jocham D., Ratliff T. L., Bhle A., NK cells are essential for effective BCG immunotherapy International Journal of Cancer 2001 92 5 697 702 (Pubitemid 32385713)
41. Bhle A., Thanhuser A., Ulmer A. J., Ernst M., Flad H. D., Jocham D., Dissecting the immunobiological effects of bacillus Calmette-Guérin (BCG) in vitro: evidence of a distinct BCG-activated killer (BAK) cell phenomenon Journal of Urology 1993 150 6 1932 1937 (Pubitemid 24350840)
42. Brandau S., Bhle A., Thanhuser A., Ernst M., Mattern T., Ulmer A. J., Flad H. D., In vitro generation of bacillus Calmette-Guérin-activated killer cells Clinical Infectious Diseases 2000 31 supplement 3 S94 S100 (Pubitemid 32269598)
43. Brandau S., Suttmann H., Riemensberger J., Seitzer U., Arnold J., Durek C., Jocham D., Flad H. D., Bohle A., Perforin-mediated lysis of tumor cells by Mycobacterium bovis Bacillus Calmette-Guérin-activated killer cells Clinical Cancer Research 2000 6 9 3729 3738
44. Jackson A. M., Hawkyard S. J., Prescott S., Ritchie A. W. S., James K., Chisholm G. D., An investigation of factors influencing the in vitro induction of LAK activity against a variety of human bladder cancer cell lines Journal of Urology 1992 147 1 207 211
45. Shemtov M. M., Cheng D. L. W., Kong L., Shu W. P., Sassaroli M., Droller M. J., Liu B. C. S., LAK cell mediated apoptosis of human bladder cancer cells involves a pH- dependent endonuclease system in the cancer cell: possible mechanism of BCG therapy Journal of Urology 1995 154 1 269 274
46. Kawashima T., Norose Y., Watanabe Y., Enomoto Y., Narazaki H., Watari E., Tanaka S., Takahashi H., Yano I., Brenner M. B., Sugita M., Cutting edge: major CD8 T cell response to live bacillus Calmette-Guérin is mediated by CD1 molecules Journal of Immunology 2003 170 11 5345 5348 (Pubitemid 36617817)
47. Higuchi T., Shimizu M., Owaki A., Takahashi M., Shinya E., Nishimura T., Takahashi H., A possible mechanism of intravesical BCG therapy for human bladder carcinoma: involvement of innate effector cells for the inhibition of tumor growth Cancer Immunology and Immunotherapy 2009 58 8 1245 1255
48. Emoto M., Emoto Y., Buchwalow I. B., Kaufmann S. H. E., Induction of IFN-gamma-producing CD4+ natural killer T cells by Mycobacterium bovis bacillus Calmette Guérin The European Journal of Immunology 1999 29 2 650 659 (Pubitemid 29078527)
49. Aderem A., Ulevitch R. J., Toll-like receptors in the induction of the innate immune response Nature 2000 406 6797 782 787
50. Bilen C. Y., Inci K., Erkan I., zen H., The predictive value of purified protein derivative results on complications and prognosis in patients with bladder cancer treated with bacillus Calmette-Guérin Journal of Urology 2003 169 5 1702 1705 (Pubitemid 36443475)
51. Reale M., Intorno R., Tenaglia R., Feliciani C., Barbacane R. C., Santoni A., Conti P., Production of MCP-1 and RANTES in bladder cancer patients after bacillus Calmette-Guérin immunotherapy Cancer Immunology and Immunotherapy 2002 51 2 91 98 (Pubitemid 34230723)
52. Pook S. H., Rahmat J. N., Esuvaranathan K., Mahendran R., Internalization of Mycobacterium bovis, Bacillus Calmette Guerin, by bladder cancer cells is cytotoxic Oncology Reports 2007 18 5 1315 1320
53. Ikeda N., Toida I., Iwasaki A., Kawai K., Akaza H., Surface antigen expression on bladder tumor cells induced by bacillus Calmette-Guérin (BCG): a role of BCG internalization into tumor cells International Journal of Urology 2002 9 1 29 35 (Pubitemid 34309964)
54. Saban M. R., Hellmich H. L., Simpson C., Davis C. A., Lang M. L., Ihnat M. A., O'Donnell M. A., Wu X. R., Saban R., Repeated BCG treatment of mouse bladder selectively stimulates small GTPases and HLA antigens and inhibits single-spanning uroplakins BMC Cancer 2007 7, article 204
55. Chen F. H., Crist S. A., Zhang G. J., Iwamoto Y., See W. A., Interleukin-6 production by human bladder tumor cell lines is up-regulated by bacillus Calmette-Guérin through nuclear factor-kappaB and Ap-1 via an immediate early pathway Journal of Urology 2002 168 2 786 797 (Pubitemid 34793363)
56. Zhang G., Chen F., Cao Y., See W. A., Bacillus Calmette-Guérin induces p21 expression in human transitional carcinoma cell lines via an immediate early, p53 independent pathway Urologic Oncology 2007 25 3 221 227 (Pubitemid 46670753)
57. Chen F., Zhang G., Iwamoto Y., See W. A., BCG directly induces cell cycle arrest in human transitional carcinoma cell lines as a consequence of integrin cross-linking BMC Urology 2005 5, article 8
58. Ping S. Y., Wu C. L., Yu D. S., Sunitinib can enhance BCG mediated cytotoxicity to transitional cell carcinoma through apoptosis pathway. Urologic Oncology. In press
59. See W. A., Zhang G., Chen F., Cao Y., Langenstroer P., Sandlow J., Bacille-Calmette Gurin induces caspase-independent cell death in urothelial carcinoma cells together with release of the necrosis-associated chemokine high molecular group box protein 1 The British Journal of Urology International 2009 103 12 1714 1720
60. See W. A., Zhang G., Chen F., Cao Y., P21 Expression by human urothelial carcinoma cells modulates the phenotypic response to BCG Urologic Oncology 2010 28 5 526 533
61. O'Donnell M. A., Krohn J., DeWolf W. C., Salvage intravesical therapy with interferon-alpha 2b plus low dose bacillus Calmette-Guerin is effective in patients with superficial bladder cancer in whom bacillus Calmette-Guerin alone previously failed Journal of Urology 2001 166 4 1300 1304 (Pubitemid 32862161)
62. Lam J. S., Benson M. C., O'Donnell M. A., Sawczuk A., Gavazzi A., Wechsler M. H., Sawczuk I. S., Bacillus Calmete-Guérin plus interferon-alpha2B intravesical therapy maintains an extended treatment plan for superficial bladder cancer with minimal toxicity Urologic Oncology 2003 21 5 354 360 (Pubitemid 38534176)
63. Joudi F. N., Smith B. J., O'Donnell M. A., Final results from a national multicenter phase II trial of combination bacillus Calmette-Guérin plus interferon alpha-2B for reducing recurrence of superficial bladder cancer Urologic Oncology 2006 24 4 344 348 (Pubitemid 43963411)
64. Nepple K. G., Lightfoot A. J., Rosevear H. M., O'Donnell M. A., Lamm D. L., Bacillus Calmette-Guérin with or without interferon -2b and megadose versus recommended daily allowance vitamins during induction and maintenance intravesical treatment of nonmuscle invasive bladder cancer Journal of Urology 2010 184 5 1915 1919
65. Bazarbashi S., Soudy H., Abdelsalam M., Co-administration of intravesical bacillus Calmette-Guérin and interferon -2B as first line in treating superficial transitional cell carcinoma of the urinary bladder. The British Journal of Urology International. In press
66. Den Otter W., Dobrowolski Z., Bugajski A., Papla B., Van Der Meijden A. P. M., Koten J. W., Boon T. A., Siedlar M., Zembala M., Intravesical interleukin-2 in T1 papillary bladder carcinoma: regression of marker lesion in 8 of 10 patients Journal of Urology 1998 159 4 1183 1186 (Pubitemid 28172790)
67. Tubaro A., Stoppacciaro A., Velotti F., Bossola P. C., Cusumano G., Vicentini C., De Carli P., Ruco L., Santoni A., Cancrini A., Giuffrida M., Cippitelli M., Palmer P. A., Miano L., Local immunotherapy of superficial bladder cancer by intravesical instillation of recombinant interleukin-2 The European Urology 1995 28 4 297 303
68. Ferlazzo G., Magno C., Iemmo R., Rizzo M., Lupo G., Semino C., Bruno S., Meliol G., Treatment of superficial bladder cancer with intravesical perfusion of rIL-2: a follow-up study Anticancer Research 1996 16 2 979 980 (Pubitemid 26182043)
69. Weiss G. R., O'Donnell M. A., Loughlin K., Zonno K., Laliberte R. J., Sherman M. L., Phase 1 study of the intravesical administration of recombinant human interleukin-12 in patients with recurrent superficial transitional cell carcinoma of the bladder Journal of Immunotherapy 2003 26 4 343 348 (Pubitemid 36858718)
70. Zaharoff D. A., Hoffman B. S., Hooper H. B., Benjamin C. J., Khurana K. K., Hance K. W., Rogers C. J., Pinto P. A., Schlom J., Greiner J. W., Intravesical immunotherapy of superficial bladder cancer with chitosan/interleukin-12 Cancer Research 2009 69 15 6192 6199
71. Giannopoulos A., Constantinides C., Fokaeas E., Stravodimos C., Giannopoulou M., Kyroudi A., Gounaris A., The immunomodulating effect of interferon-gamma intravesical instillations in preventing bladder cancer recurrence Clinical Cancer Research 2003 9 15 5550 5558 (Pubitemid 37499474)
72. Stavropoulos N. E., Hastazeris K., Filiadis I., Mihailidis I., Ioachim E., Liamis Z., Kalomiris P., Intravesical instillations of interferon gamma in the prophylaxis of high risk superficial bladder cancerresults of a controlled prospective study Scandinavian Journal of Urology and Nephrology 2002 36 3 218 222 (Pubitemid 34793509)
73. Stravoravdi P., Toliou T., Kirtsis P., Natsis K., Konstandinidis E., Barich A., Gigis P., Dimitriadis K., A new approach in the management of urothelial tumors using GM-CSF on marker lesions: an ultrastructural and immunohistochemical study on the macrophage population in bladder mucosa Journal of Interferon and Cytokine Research 1999 19 3 221 225 (Pubitemid 29165830)
74. Theano T., Pelagia S., Konstantinos N., Petros K., Alfred B., Konstantinos D., Panagiotis G., Lymphocyte activation by granulocyte macrophage-colony stimulating factor in human bladder cancer Journal of Experimental Therapeutics and Oncology 2002 2 3 153 157 (Pubitemid 34663460)
75. Luo Y., Chen X., Downs T. M., DeWolf W. C., O'Donnell M. A., IFN-alpha 2B enhances Th1 cytokine responses in bladder cancer patients receiving Mycobacterium bovis bacillus Calmette-Guérin immunotherapy Journal of Immunology 1999 162 4 2399 2405 (Pubitemid 29288868)
76. Luo Y., Chen X., O'Donnell M. A., Role of Th1 and Th2 cytokines in BCG-induced IFN-gamma production: cytokine promotion and simulation of BCG effect Cytokine 2003 21 1 17 26 (Pubitemid 36369372)
77. O'Donnell M. A., Luo Y., Chen X., Szilvasi A., Hunter S. E., Clinton S. K., Role of IL-12 in the induction and potentiation of IFN-gamma in response to bacillus Calmette-Guérin Journal of Immunology 1999 163 8 4246 4252 (Pubitemid 29474489)
78. Bastos R. G., Borsuk S., Seixas F. K., Dellagostin O. A., Recombinant Mycobacterium bovis BCG Vaccine 2009 27 47 6495 6503
79. Jacobs W. R. Jr., Tuckman M., Bloom B. R., Introduction of foreign DNA into mycobacteria using a shuttle phasmid Nature 1987 327 6122 532 535 (Pubitemid 17085824)
80. Snapper S. B., Lugosi L., Jekkel A., Melton R. E., Kieser T., Bloom B. R., Jacobs W. R., Lysogeny and transformation in mycobacteria: stable expression of foreign genes Proceedings of the National Academy of Sciences of the United States of America 1988 85 18 6987 6991
81. Stover C. K., de la Cruz V. F., Fuerst T. R., Burlein J. E., Benson L. A., Bennett L. T., Bansal G. P., Young J. F., Lee M. H., Hatfull G. F., Snapper S. B., Barletta R. G., Jacobs W. R., Bloom B. R., New use of BCT for recombinant vaccines Nature 1991 351 6326 456 460 (Pubitemid 21896614)
82. Lee M. H., Pascopella L., Jacobs W. R. Jr., Hatfull G. F., Site-specific integration of mycobacteriophage L5: integration-proficient vectors for Mycobacterium smegmatis, Mycobacterium tuberculosis, and bacille Calmette-Guérin Proceedings of the National Academy of Sciences of the United States of America 1991 88 8 3111 3115 (Pubitemid 21916569)
83. Stover C. K., Bansal G. P., Hanson M. S., Burlein J. E., Palaszynski S. R., Young J. F., Koenig S., Young D. B., Sadziene A., Barbour A. G., Protective immunity elicited by recombinant bacille Calmette-Guérin (BCG) expressing outer surface protein A (OspA) lipoprotein: a candidate Lyme disease vaccine Journal of Experimental Medicine 1993 178 1 197 209 (Pubitemid 23173255)
84. Aldovini A., Young R. A., Humoral and cell-mediated immune responses to live recombinant BCG-HIV vaccines Nature 1991 351 6326 479 482 (Pubitemid 21896623)
85. Connell N. D., Medina-Acosta E., McMaster W. R., Bloom B. R., Russell D. G., Effective immunization against cutaneous leishmaniasis with recombinant bacille Calmette-Guérin expressing the Leishmania surface proteinase gp63 Proceedings of the National Academy of Sciences of the United States of America 1993 90 24 11473 11477 (Pubitemid 24008661)
86. Langermann S., Palaszynski S. R., Burlein J. E., Koenig S., Hanson M. S., Briles D. E., Stover C. K., Protective humoral response against pneumococcal infection in mice elicited by recombinant Bacille Calmette-Guérin vaccines expressing pneumococcal surface protein A Journal of Experimental Medicine 1994 180 6 2277 2286
87. Langermann S., Palaszynski S., Sadziene A., Stover C. K., Koenig S., Systemic and mucosal immunity induced by BCG vector expressing outer-surface protein A of Borrelia burgdorferi Nature 1994 372 6506 552 555 (Pubitemid 24368537)
88. Matsuo K., Yamaguchi R., Yamazaki A., Tasaka H., Terasaka K., Totsuka M., Kobayashi K., Yukitake H., Yamada T., Establishment of a foreign antigen secretion system in mycobacteria Infection and Immunity 1990 58 12 4049 4054
89. Grode L., Kursar M., Fensterle J., Kaufmann S. H. E., Hess J., Cell-mediated immunity induced by recombinant Mycobacterium bovis Bacille Calmette-Guérin strains against an intracellular bacterial pathogen: importance of antigen secretion or membrane-targeted antigen display as lipoprotein for vaccine efficacy Journal of Immunology 2002 168 4 1869 1876 (Pubitemid 34135788)
90. Murray A., Winter N., Lagranderie M., Hill D. F., Rauzier J., Timm J., Leclerc C., Moriarty K. M., Gheorghiu M., Gicquel B., Expression of Escherichia coli beta-galactosidase in Mycobacterium bovis BCG using an expression system isolated from Mycobacterium paratuberculosis which induced humoral and cellular immune responses Molecular Microbiology 1992 6 22 3331 3342
91. Honda M., Matsuo K., Nakasone T., Okamoto Y., Yoshizaki H., Kitamura K., Sugiura W., Watanabe K., Fukushima Y., Haga S., Katsura Y., Tasaka H., Komuro K., Yamada T., Asano T., Yamazaki A., Yamazaki S., Protective immune responses induced by secretion of a chimeric soluble protein from a recombinant Mycobacterium bovis bacillus Calmette-Guérin vector candidate vaccine for human immunodeficiency virus type 1 in small animals Proceedings of the National Academy of Sciences of the United States of America 1995 92 23 10693 10697
92. Horwitz M. A., Harth G., Dillon B. J., Maslesa-Galic S., Recombinant bacillus Calmette-Guérin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity againts tuberculosis than conventional BCG vaccines in a highly susceptible animal model Proceedings of the National Academy of Sciences of the United States of America 2000 97 25 13853 13858
93. Geliebter J., Immunotherapy for prostate cancer using recombinant bacille Calmette-Guérin expressing prostate specific antigens United States Patent Application 20100316668 2010
94. Elzey B. D., Siemens D. R., Ratliff T. L., Lubaroff D. M., Immunization with type 5 adenovirus recombinant for a tumor antigen in combination with recombinant canarypox virus (ALVAC) cytokine gene delivery induces destruction of established prostate tumors International Journal of Cancer 2001 94 6 842 849 (Pubitemid 33032833)
95. He J., Shen D., O'Donnell M. A., Chang H. R., Induction of MUC1-specific cellular immunity by a recombinant BCG expressing human MUC1 and secreting IL2 International Journal of Oncology 2002 20 6 1305 1311
96. Chung M. A., Luo Y., O'Donnell M., Rodriguez C., Heber W., Sharma S., Chang H. R., Development and preclinical evaluation of a Bacillus Calmette-Guérin-MUC1-based novel breast cancer vaccine Cancer Research 2003 63 6 1280 1287 (Pubitemid 36348706)
97. Yuan S., Shi C., Han W., Ling R., Li N., Wang T., Effective anti-tumor responses induced by recombinant bacillus Calmette-Guérin vaccines based on different tandem repeats of MUC1 and GM-CSF The European Journal of Cancer Prevention 2009 18 5 416 423
98. Yuan S., Shi C., Lv Y., Wang T., Wang H., Han W., A novel Bacillus Calmette-Guérin-based breast cancer vaccine that coexpresses multiple tandem repeats of MUC1 and CD80 breaks the immune tolerance and inhibits MUC1-positive breast cancer growth Cancer Biotherapy and Radiopharmaceuticals 2009 24 5 607 613
99. Yuan S., Shi C., Ling R., Wang T., Wang H., Han W., Immunization with two recombinant Bacillus Calmette-Guérin vaccines that combine the expression of multiple tandem repeats of mucin-1 and colony stimulating-factor suppress breast tumor growth in mice Journal of Cancer Research and Clinical Oncology 2010 136 9 1359 1367
100. O'Donnell M. A., Aldovini A., Duda R. B., Yang H., Szilvasi A., Young R. A., DeWolf W. C., Recombinant Mycobacterium bovis BCG secreting functional interleukin-2 enhances gamma interferon production by splenocytes Infection and Immunity 1994 62 6 2508 2514 (Pubitemid 24157083)
101. Duda R. B., Yang H., Dooley D. D., Abu-Jawdeh G., Recombinant BCG therapy suppresses melanoma tumor growth Annals of Surgical Oncology 1995 2 6 542 549
102. Kong D., Kunimoto D. Y., Secretion of human interleukin 2 by recombinant Mycobacterium bovis BCG Infection and Immunity 1995 63 3 799 803
103. Murray P. J., Aldovini A., Young R. A., Manipulation and potentiation of antimycobacterial immunity using recombinant bacille Calmette-Guérin strains that secrete cytokines Proceedings of the National Academy of Sciences of the United States of America 1996 93 2 934 939
104. Ryan A. A., Wozniak T. M., Shklovskaya E., O'Donnell M. A., De St Groth B. F., Britton W. J., Triccas J. A., Improved protection against disseminated tuberculosis by Mycobacterium bovis bacillus Calmette-Guérin secreting murine GM-CSF is associated with expansion and activation of APCs Journal of Immunology 2007 179 12 8418 8424
105. Wangoo A., Brown I. N., Marshall B. G., Cook H. T., Young D. B., Shaw R. J., Bacille Calmette-Guérin (BCG)-associated inflammation and fibrosis: modulation by recombinant BCG expressing interferon-gamma (IFN-gamma) Clinical and Experimental Immunology 2000 119 1 92 98 (Pubitemid 30064596)
106. Slobbe L., Lockhart E., O'Donnell M. A., Mackintosh C., De Lisle G., Buchan G., An in vivo comparison of bacillus Calmette-Guérin (BCG) and cytokine- secreting BCG vaccines Immunology 1999 96 4 517 523 (Pubitemid 29179788)
107. Young S. L., O'Donnell M. A., Buchan G. S., IL-2-secreting recombinant bacillus Calmette Guerin can overcome a Type 2 immune response and corticosteroid-induced immunosupression to elicit a Type 1 immune response International Immunology 2002 14 7 793 800 (Pubitemid 34814640)
108. Young S., O'Donnell M., Lockhart E., Buddle B., Slobbe L., Luo Y., De Lisle G., Buchan G., Manipulation of immune responses to Mycobacterium bovis by vaccination with IL-2- and IL-18-secreting recombinant bacillus Calmette Guerin Immunology and Cell Biology 2002 80 3 209 215 (Pubitemid 34639370)
109. Luo Y., Chen X., Szilvasi A., O'Donnell M. A., Co-expression of interleukin-2 and green fluorescent protein reporter in mycobacteria: in vivo application for monitoring antimycobacterial immunity Molecular Immunology 2000 37 9 527 536 (Pubitemid 32001694)
110. Moreira A. L., Tsenova L., Murray P. J., Freeman S., Bergtold A., Chiriboga L., Kaplan G., Aerosol infection of mice with recombinant BCG secreting murine IFN-gamma partially reconstitutes local protective immunity Microbial Pathogenesis 2000 29 3 175 185
111. Luo Y., Chen X., Han R., O'Donnell M. A., Recombinant bacille Calmette-Guérin (BCG) expressing human interferon-alpha 2B demonstrates enhanced immunogenicity Clinical and Experimental Immunology 2001 123 2 264 270 (Pubitemid 32174778)
112. Chen X., O'Donnell M. A., Luo Y., Dose-dependent synergy of Th1-stimulating cytokines on bacille Calmette-Guérin-induced interferon-gamma production by human mononuclear cells Clinical and Experimental Immunology 2007 149 1 178 185 (Pubitemid 46897114)
113. Biet F., Kremer L., Wolowczuk I., Delacre M., Locht C., Mycobacterium bovis BCG producing Interleukin-18 increases antigen-specific gamma interferon production in mice Infection and Immunity 2002 70 12 6549 6557 (Pubitemid 35387880)
114. Biet F., Duez C., Kremer L., Marquillies P., Amniai L., Tonnel A. B., Locht C., Pestel J., Recombinant Mycobacterium bovis BCG producing IL-18 reduces IL-5 production and bronchoalveolar eosinophilia induced by an allergic reaction Allergy 2005 60 8 1065 1072 (Pubitemid 40942763)
115. Arnold J., de Boer E. C., O'Donnell M. A., Bhle A., Brandau S., Immunotherapy of experimental bladder cancer with recombinant BCG expressing interferon-gamma Journal of Immunotherapy 2004 27 2 116 123 (Pubitemid 38282731)
116. Fan X. L., Yu T. H., Gao Q., Yao W., Immunological properties of recombinant Mycobacterium bovis bacillus Calmette-Guérin strain expressing fusion protein IL-2-ESAT-6 Acta Biochimica et Biophysica Sinica 2006 38 10 683 690 (Pubitemid 44657212)
117. Ryan A. A., Spratt J. M., Britton W. J., Triccas J. A., Secretion of functional monocyte chemotactic protein 3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection Infection and Immunity 2007 75 1 523 526 (Pubitemid 46047931)
118. Xu Y., Zhu B., Wang Q., Chen J., Qie Y., Wang J., Wang H., Wang B., Wang H., Recombinant BCG coexpressing Ag85B, ESAT-6 and mouse-IFN-gamma confers effective protection against Mycobacterium tuberculosis in C57BL/6 mice FEMS Immunology and Medical Microbiology 2007 51 3 480 487 (Pubitemid 350076157)
119. Tang C., Yamada H., Shibata K., Maeda N., Yoshida S., Wajjwalku W., Ohara N., Yamada T., Kinoshita T., Yoshikai Y., Efficacy of recombinant bacille Calmette-Guérin vaccine secreting interleukin-15/antigen 85B fusion protein in providing protection against Mycobacterium tuberculosis Journal of Infectious Diseases 2008 197 9 1263 1274 (Pubitemid 351632757)
120. Shen H., Wang C., Yang E., Xu Y., Liu W., Yan J., Wang F., Wang H., Novel recombinant BCG coexpressing Ag85B, ESAT-6 and mouse TNF-alpha induces significantly enhanced cellular immune and antibody responses in C57BL/6 mice Microbiology and Immunology 2010 54 8 435 441
121. Soualhine H., Deghmane A. E., Sun J., Mak K., Talal A., Av-Gay Y., Hmama Z., Mycobacterium bovis bacillus Calmette-Guérin secreting active cathepsin S stimulates expression of mature MHC class II molecules and antigen presentation in human macrophages Journal of Immunology 2007 179 8 5137 5145
122. Biet F., Kremer L., Wolowczuk I., Delacre M., Locht C., Immune response induced by recombinant Mycobacterium bovis BCG producing the cholera toxin B subunit Infection and Immunity 2003 71 5 2933 2937 (Pubitemid 36519913)
123. Chade D. C., Borra R. C., Nascimento I. P., Villanova F. E., Leite L. C. C., Andrade E., Srougi M., Ramos K. L., Andrade P. M., Immunomodulatory effects of recombinant BCG expressing pertussis toxin on TNF-alpha and IL-10 in a bladder cancer model Journal of Experimental and Clinical Cancer Research 2008 27 1, article 78
124. Andrade P. M., Chade D. C., Borra R. C., Nascimento I. P., Villanova F. E., Leite L. C. C., Andrade E., Srougi M., The therapeutic potential of recombinant BCG expressing the antigen S1PT in the intravesical treatment of bladder cancer Urologic Oncology 2010 28 5 520 525
125. Van Faassen H., Dudani R., Krishnan L., Sad S., Prolonged antigen presentation, APC-, and CD8+ T cell turnover during mycobacterial infection: comparison with Listeria monocytogenes Journal of Immunology 2004 172 6 3491 3500 (Pubitemid 38337929)
126. Luo Y., Szilvasi A., Chen X., DeWolf W. C., O'Donnell M. A., A novel method for monitoring Mycobacterium bovis BCG trafficking with recombinant BCG expressing green fluorescent protein Clinical and Diagnostic Laboratory Immunology 1996 3 6 761 768 (Pubitemid 26388816)
127. Hulseberg P. D., Zozulya A., Chu H. H., Triccas J. A., Fabry Z., Sandor M., The same well-characterized T cell epitope SIINFEKL expressed in the context of a cytoplasmic or secreted protein in BCG induces different CD8+ T cell responses Immunology Letters 2010 130 1-2 36 42
128. Young S. L., Murphy M., Zhu X. W., Harnden P., O'Donnell M. A., James K., Patel P. M., Selby P. J., Jackson A. M., Cytokine-modified Mycobacterium smegmatis as a novel anticancer immunotherapy International Journal of Cancer 2004 112 4 653 660 (Pubitemid 39425946)
129. Haley J. L., Young D. G., Alexandroff A., James K., Jackson A. M., Enhancing the immunotherapeutic potential of mycobacteria by transfection with tumour necrosis factor-alpha Immunology 1999 96 1 114 121 (Pubitemid 29030588)